Efficacy of Telithromycin (HMR 3647) against Enterococci in a Mouse Peritonitis Model
AUTOR(ES)
Singh, Kavindra V.
FONTE
American Society for Microbiology
RESUMO
We used a mouse peritonitis model to evaluate the in vivo efficacy of telithromycin (HMR 3647) (TEL) and erythromycin (ERY) against four strains of Enterococcus faecalis and three strains of Enterococcus faecium with differing susceptibilities to TEL. TEL was highly active in vivo against Ery-susceptible (Erys) and -intermediate (Eryi) strains (MIC of TEL = 0.015 to 0.062 μg/ml) and showed less efficacy against Ery-resistant (Eryr) isolates (MIC of TEL = 4 to 16 μg/ml), although this was overcome in part by a second subcutaneous dose. Quinupristin-dalfopristin was also noted to have less efficacy against Eryr versus Erys or Eryi E. faecium strains, but this difference was reduced by intravenous administration. In conclusion, TEL was more potent in vivo against enterococci than was ERY; its activity was lowered by the presence of erm(B)-mediated Eryr.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=90218Documentos Relacionados
- Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647)
- In Vivo Efficacy of the New Ketolide Telithromycin (HMR 3647) in Murine Infection Models
- In Vitro Activities of the Novel Ketolide Telithromycin (HMR 3647) against Erythromycin-Resistant Streptococcus Species
- In Vitro Susceptibilities of Rapidly Growing Mycobacteria to Telithromycin (HMR 3647) and Seven Other Antimicrobials
- Pharmacokinetics of the New Ketolide Telithromycin (HMR 3647) Administered in Ascending Single and Multiple Doses
